Mavacamten is the first and only licensed selective, allosteric and reversible cardiac myosin inhibitor for symptomatic NYHA class II and III
obstructive HCM.1
Mavacamten is the only licensed non-invasive oral therapy that targets the underlying pathophysiology of obstructive HCM by reducing excess formation of myosin-actin cross bridging.1–3
Mavacamten modulates the number of myosin heads that can enter power-generating states, thus reducing the probability of force-producing systolic and residual diastolic cross-bridge formation.1
